Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Executives On The Move: Biology Leader Exits Gilead, And Promotions At Mitsubishi And Sanofi

Executive Summary

Exiting Gilead biology leader lands CSO post at blood cancer company Amphivena Therapeutics. Sanofi moves its Brazil general manager to head China Emerging Markets Business Unit and Mitsubishi Tanabe Pharma America promotes area director to VP, ops and strategy.

You may also be interested in...



Coronavirus Update: Can IL-6 Drugs Cut Deaths? Kevzara Trials Start In Worst Hit Countries

News from around the biopharma sector and its efforts to meet the challenges posed by the coronavirus pandemic.

Coronavirus Update: More Companies Join Therapeutics Accelerator, FDA Delays AdCom For First NASH Drug

As the global number of COVID-19 cases exceeds 500,000 for the first time, more biopharma companies throw their weight behind Gates Foundation's drug-hunting initiative.

Coronavirus Update: BIO Facilitates COVID-19 Collaborations, ASCO Goes Virtual

BIO hosts summit to support collaborations on coronavirus vaccines and therapeutics, Vir advances COVID-19 antibody candidates, Gilead renounces orphan status for remdesivir, BMS joins Pfizer in pushing back investor meeting, and ASCO goes virtual.

Topics

UsernamePublicRestriction

Register

SC124899

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel